171 related articles for article (PubMed ID: 11841409)
1. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Voskaridou E; Terpos E; Komninaka V; Eftyhiadis E; Mantzourani M; Loukopoulos D
Br J Haematol; 2002 Jan; 116(1):155-7. PubMed ID: 11841409
[TBL] [Abstract][Full Text] [Related]
2. Thrombocytosis--report of a case.
Thomas M; Pavithran K; Salil ; Somarajan A
J Assoc Physicians India; 2000 Apr; 48(4):441-2. PubMed ID: 11273186
[TBL] [Abstract][Full Text] [Related]
3. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Silver RT
Leukemia; 2005 Jan; 19(1):39-43. PubMed ID: 15510207
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Trapp OM; Beykirch MK; Petrides PE
Blood Cells Mol Dis; 1998 Mar; 24(1):9-13. PubMed ID: 9516377
[TBL] [Abstract][Full Text] [Related]
5. Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Wirth K; Schoepf E; Mertelsmann R; Lindemann A
Br J Dermatol; 1998 Mar; 138(3):533-5. PubMed ID: 9580816
[TBL] [Abstract][Full Text] [Related]
6. Severe hypersensitivity pneumonitis associated with anagrelide.
Raghavan M; Mazer MA; Brink DJ
Ann Pharmacother; 2003 Sep; 37(9):1228-31. PubMed ID: 12921504
[TBL] [Abstract][Full Text] [Related]
7. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group.
Am J Med; 1992 Jan; 92(1):69-76. PubMed ID: 1731512
[TBL] [Abstract][Full Text] [Related]
8. [Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Voglová J; Maisnar V; Beránek M; Chrobák L
Vnitr Lek; 2006 Sep; 52(9):819-22. PubMed ID: 17091608
[TBL] [Abstract][Full Text] [Related]
9. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea and periodicity in myeloproliferative disease.
Bennett M; Grunwald AJ
Eur J Haematol; 2001 May; 66(5):317-23. PubMed ID: 11422411
[TBL] [Abstract][Full Text] [Related]
11. [Hydroxyurea, erythrocyte volumes and hemoglobin F].
Bargetzi MJ; Schönenberger A; Tichelli A; Passweg J; Rabaglio M; Singer D; Sissolak G; Gratwohl A; Speck B
Schweiz Med Wochenschr; 1995 Mar; 125(9):433-5. PubMed ID: 7534433
[TBL] [Abstract][Full Text] [Related]
12. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
13. [beta-thalassemia minor diagnosed in a patient with chronic myelogenous leukemia during hydroxyurea therapy].
Chiba K; Kurosawa M; Kondo T; Suzuki S; Musashi M; Asaka M; Imamura M; Hattori Y; Oba Y
Rinsho Ketsueki; 2000 Jan; 41(1):61-4. PubMed ID: 10695401
[TBL] [Abstract][Full Text] [Related]
14. Precipitous fall in platelet count with anagrelide: case report and critique of dosing recommendations.
McCune JS; Liles D; Lindley C
Pharmacotherapy; 1997; 17(4):822-6. PubMed ID: 9250565
[TBL] [Abstract][Full Text] [Related]
15. Anagrelide: 20 years later.
Emadi A; Spivak JL
Expert Rev Anticancer Ther; 2009 Jan; 9(1):37-50. PubMed ID: 19105705
[TBL] [Abstract][Full Text] [Related]
16. Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Cesar JM; Cabello P; Ferro T; Navarro JL
Cancer Genet Cytogenet; 2006 May; 167(1):74-7. PubMed ID: 16682291
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
18. The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy.
D'adda M; Micheletti M; Drera M; Ferrari S; Rossi G
Leuk Lymphoma; 2008 Nov; 49(11):2216-8. PubMed ID: 19021067
[No Abstract] [Full Text] [Related]
19. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.
Adler R; Viehmann S; Kuhlisch E; Martiniak Y; Röttgers S; Harbott J; Suttorp M
Eur J Haematol; 2009 Feb; 82(2):112-8. PubMed ID: 19067742
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL positive essential thrombocythaemia: a variant of chronic myelogerous leukaemia or a distinct clinical entity: a special case report.
Fadilah SA; Cheong SK
Singapore Med J; 2000 Dec; 41(12):595-8. PubMed ID: 11296785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
